Identification and quantitation of the N-acetyl-L-cysteine S-conjugates of bendamustine and its sulfoxides in human bile after administration of bendamustine hydrochloride

Drug Metabolism and Disposition

Volumn 37, Issue 2, 2009, Pages 292-301

  Teichert, Jens ^a   Sohr, Reinhard ^a   Hennig, Lothar ^a   Baumann, Frank ^a   Schoppmeyer, Konrad ^b   Patzak, Ulrich ^c   Preiss, Rainer ^a  

^a UNIVERSITY OF LEIPZIG   (Germany)

^b UNIVERSITY HOSPITAL LEIPZIG   (Germany)

^c Astellas Pharma GmbH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE DERIVATIVE; ACETYLCYSTEINE SULFOXIDE; BENDAMUSTINE; CYSTEINE CONJUGATE; GLUTATHIONE; SULFOXIDE; UNCLASSIFIED DRUG;

ARTICLE; BILIARY EXCRETION; CHEMICAL STRUCTURE; CLINICAL ARTICLE; CONJUGATION; DRUG DETERMINATION; DRUG EXCRETION; DRUG MECHANISM; DRUG METABOLISM; HUMAN; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL;

ANIMALS; BILE; GASTRIC ACID; HUMANS; IMMUNOTOXINS; NITROGEN MUSTARD COMPOUNDS; RATS; SULFOXIDES;

RATTUS;

EID: 59649098577     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.108.022855     Document Type: Article

References (22)

1. Bennaceur-Griscelli A, Bosq J, Koscielny S, Lefrère F, Turhan A, Brousse N, Hermine O, and Ribrag V (2004) High level of glutathione-.S'- transferase pi expression in mantle cell lymphomas. Clin Cancer Res 10:3029-3034.
2. Bergmann MA, Goebeler ME, Herold M, Emmerich B, Wilhelm M, Ruelfs C, Boening L, and Hallek MJ (2005) Efficacy of bendamustine in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase I/II study of the German CLL Study Group. Haematologica 90:1357-1364.
3. Bezek S, Kukan M, Scasnár V, Lukácsová M, and Trnovec T (1996) Selective uptake of the anticancer drug bendamustine by liver and kidney tissues following its intravenous administration to mice. Methods Find Exp Clin Pharmacol 18:117-122.
4. Bezek S, Scasnár V, Trnovec T, and Grupe R (1991) Hepatobiliary elimination of bendamustin (Cytostasan) in rats. Pharmazie 46:810-811.
5. Bremer K (2002) High rates of long-lasting remissions after 5-day bendamustine chemotherapy cycles in pre-treated low-grade non-Hodgkin's- lymphomas. J Cancer Res Clin Oncol 128:603-609.
6. 14C]bendamustine in rat urine and bile: preliminary structural identification of metabolites. Drug Metab Dispos 35:1744-1753.
7. Friedberg JW, Cohen P, Chen L, Robinson KS, Forero-Torres A, La Casce AS, Fayad LE, Bessudo A, Camacho ES, Williams ME, et al. (2008) Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin's lymphoma: results from a phase II multicenter, single-agent study. J Clin Oncol 26:204-210.
8. Gaul L, Mandl-Weber S, Baumann P, Emmerich B, and Schmidmaier R (2008) Bendamustine induces G2 cell cycle arrest and apoptosis in myeloma cells: the role of ATM-Chk2-Cdc25A and ATM-p53-p21-pathways. JCancer Res Clin Oncol 134:245-253.
9. HeiderAand NiederleN(2001) Efficacy and toxicity ofbendamustineinpatients withrelapsed low-grade non-Hodgkin's lymphomas. Anticancer Drugs 12:725-729.
10. HinchmanCA, Matsumoto H, Simmons TW, and Ballatori N (1991) Intrahepatic conversionof a glutathione conjugate to its mercapturic acid: metabolism of 1-chloro-2,4-dinitrobenzene in isolated perfused rat and guinea pig livers. J Biol Chem 266:22179-22185.
11. Konstantinov SM, Kostovski A, Topashka-Ancheva M, Genova M, and Berger MR (2002) Cytotoxic efficacy of bendamustine in human leukemia and breast cancer cell lines. J Cancer Res Clin Oncol 128:271-278.
12. Leoni LM, Bailey B, Reifert J, Bendall HH, Zeller RW, Corbeil J, Elliott G, and Niemeyer CC (2008) Bendamustine (Treanda) displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other alkylating agents. Clin Cancer Res 14:309-317.
13. Lissitchkov T, Arnaudov G, Peytchev D, and Merkle Kh (2006) Phase-I/II study to evaluate dose limiting toxicity, maximum tolerated dose, and tolerability of bendamustine HCl in pre-treated patients with B-chronic lymphocytic leukaemia (Binet stages B and C) requiring therapy. J Cancer Res Clin Oncol 132:99-104.
14. Pandya U, Srivastava SK, Singhal SS, Pal A, Awasthi S, Zimniak P, Awasthi YC, and Singh SV (2000) Activity of allelic variants of Pi class human glutathione S-transferase toward chlorambucil. Biochem Biophys Res Commun 278:258-262.
15. Parker LJ, Ciccone S, Italiano LC, Primavera A, Oakley AJ, Morton CJ, Hancock NC, Bello ML, and Parker MW (2008) The anti-cancer drug chlorambucil as a substrate for the human polymorphic enzyme glutathione transferase P1-1: kinetic properties and crystallographic characterisation of allelic variants. J Mol Biol 380:131-144.
16. Preiss R, Sohr R, Matthias M, Brockmann B, and Hüller H (1985) The pharmacokinetics of bendamustine (Cytostasane) in humans. Pharmazie 40:782-784.
17. Schwänen C, Hecker T, Hübinger G, Wölfle M, Rittgen W, Bergmann L, and Karakas T (2002) In vitro evaluation of bendamustine induced apoptosis in B-chronic lymphocytic leukemia. Leukemia 16:2096-2105.
18. Strumberg D, Harstrick A, Doll K, Hoffmann B, and Seeber S (1996) Bendamustine hydrochloride activity against doxorubicin-resistant human breast carcinoma cell lines. Anticancer Drugs 7:415-421.
19. Teichert J, Baumann F, Chao Q, Franklin C, Bailey B, Hennig L, Caca K, Schoppmeyer K, Patzak U, and Preiss R (2007) Characterization of two phase I metabolites of bendamustine in human liver microsomes and in cancer patients treated with bendamustine hydrochloride. Cancer Chemother Pharmacol 59:759-770.
20. Teichert J, Sohr R, Baumann F, Hennig L, Merkle K, Caca K, and Preiss R (2005) Synthesis and characterization of some new phase II metabolites of the alkylator bendamustine and their identification in human bile, urine, and plasma from patients with cholangiocarcinoma. Drug Metab Dispos 33:984-992.
21. Weber H, Amlacher R, Preiss R, and Hoffmann H (1991) Pharmacokinetics of bendamustin (Cytostasan) in B6D2F1-mice. Pharmazie 46:589-591.
22. Zhang L and Hanigan MH (2003) Role of cysteine S-conjugate β-lyase in the metabolism of cisplatin. J Pharmacol Exp Ther 306:988-994.